Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks

Objective To generate comparative efficacy evidence of belimumab versus anifrolumab in SLE that can inform treatment practices.Methods The SLE Responder Index (SRI)-4 response at 52 weeks of belimumab versus anifrolumab was evaluated with an indirect treatment comparison. The evidence base consisted...

Full description

Bibliographic Details
Main Authors: Michelle Petri, George K Bertsias, Antonis Fanouriakis, Binod Neupane, Roger A Levy, Amber Martin, Deven Chauhan, Pragya Shukla, Mahmoud Slim, Alfred H J Kim, Nick Ballew
Format: Article
Language:English
Published: BMJ Publishing Group 2023-01-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/10/1/e000907.full

Internet

https://lupus.bmj.com/content/10/1/e000907.full

Similar Items